Literature DB >> 2222011

Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

J A van Heerden1, C S Grant, H Gharib, I D Hay, D M Ilstrup.   

Abstract

Thirty-one patients with persistent hypercalcitoninemia after seemingly adequate primary operation for medullary thyroid carcinoma (MTC) were followed for a mean period of 11.9 years after operation. Ten patients had sporadic MTC and the remaining patients were members of families with multiple endocrine neoplasia (MEN)--either MEN 2A (15 patients) or MEN 2B (six patients). Overall 5- and 10-year survival rates were 90% and 86%, respectively. Only four patients died at the completion of the study: two of MTC and two of unrelated causes. Eleven patients (35.5%) underwent surgical re-exploration after demonstration of recurrent disease clinically or radiologically. In no patient did the calcitonin level return to normal after re-exploration. The presence of more than three metastatic nodes at the time of initial operation was a statistically significant (p = 0.003) predictor for disease recurrence. Factors approaching statistical significance were patients younger than age 35 (p = 0.06) and the percentage of cells in the S phase of cell division (0.07). This data supports a conservative surgical philosophy in the management of the patient with persistent hypercalcitoninemia after resection of MTC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2222011      PMCID: PMC1358266          DOI: 10.1097/00000658-199010000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  26 in total

1.  Medullary carcinoma of the thyroid: management of persistent hypercalcitonaemia utilizing [99mTc] (v) dimercaptosuccinic acid scintigraphy.

Authors:  R Udelsman; O A Mojiminiyi; N D Soper; I D Buley; B J Shepstone; N E Dudley
Journal:  Br J Surg       Date:  1989-12       Impact factor: 6.939

2.  THYROID ORIGIN OF CALCITONIN.

Authors:  G V FOSTER; A BAGHDIANTZ; M A KUMAR; E SLACK; H A SOLIMAN; I MACINTYRE
Journal:  Nature       Date:  1964-06-27       Impact factor: 49.962

3.  Epidemiology of medullary carcinoma of the thyroid gland: a 5-year experience (1971-1976).

Authors:  G W Sizemore; J A Carney; H Heath
Journal:  Surg Clin North Am       Date:  1977-08       Impact factor: 2.741

4.  Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma.

Authors:  M D Ben Mrad; P Gardet; A Roche; P Rougier; C Calmettes; P Motte; C Parmentier
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

5.  Discordance between plasma calcitonin and tumor-cell mass in medullary thyroid carcinoma.

Authors:  D L Trump; G Mendelsohn; S B Baylin
Journal:  N Engl J Med       Date:  1979-08-02       Impact factor: 91.245

Review 6.  Medullary carcinoma of the thyroid gland.

Authors:  G W Sizemore
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

7.  US-guided biopsy of neck masses in postoperative management of patients with thyroid cancer.

Authors:  R T Sutton; C C Reading; J W Charboneau; E M James; C S Grant; I D Hay
Journal:  Radiology       Date:  1988-09       Impact factor: 11.105

8.  Localization and resection of clinically inapparent medullary carcinoma of the thyroid.

Authors:  J A Norton; J L Doppman; M F Brennan
Journal:  Surgery       Date:  1980-06       Impact factor: 3.982

Review 9.  Advances in the diagnosis and treatment of medullary thyroid carcinoma.

Authors:  L M Brunt; S A Wells
Journal:  Surg Clin North Am       Date:  1987-04       Impact factor: 2.741

10.  The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase.

Authors:  S M Lippman; G Mendelsohn; D L Trump; S A Wells; S B Baylin
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

View more
  37 in total

1.  Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival.

Authors:  Isabel Peixoto Callejo; José Américo Brito; Carlos Manuel Zagalo; Jorge Rosa Santos
Journal:  Clin Transl Oncol       Date:  2006-06       Impact factor: 3.405

2.  Long-term outcome of reoperations for medullary thyroid carcinoma.

Authors:  Elizabeth Fialkowski; Mary DeBenedetti; Jeffrey Moley
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 3.  Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.

Authors:  Giuseppe Costante; Cosimo Durante; Zélia Francis; Martin Schlumberger; Sebastiano Filetti
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

4.  Medullary thyroid carcinoma in Northern Ireland, 1967-1997.

Authors:  S J Dolan; C F Russell
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

5.  Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection.

Authors:  J F Moley; M K DeBenedetti
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

6.  Improved results of cervical reoperation for medullary thyroid carcinoma.

Authors:  J F Moley; W G Dilley; M K DeBenedetti
Journal:  Ann Surg       Date:  1997-06       Impact factor: 12.969

7.  2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

Authors:  M Schlumberger; L Bastholt; H Dralle; B Jarzab; F Pacini; J W A Smit
Journal:  Eur Thyroid J       Date:  2012-03-28

Review 8.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

9.  Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.

Authors:  N Neuhold; F Längle; M Gnant; U Hollenstein; B Niederle
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma.

Authors:  H Dralle; I Damm; G F Scheumann; J Kotzerke; E Kupsch; H Geerlings; R Pichlmayr
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.